Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

Leukemia and Lymphoma

Volumn 51, Issue 1, 2010, Pages 85-88

  Sher, Taimur ^a   Miller, Kena C ^a   Lawrence, David ^a   Whitworth, Amy ^a   Hernandez Ilizaliturri, Francisco ^a   Czuczman, Myron S ^a   Miller, Austin ^a   Lawrence, William ^b   Bilgrami, Syed Ali ^c   Sood, Raman ^b   Wood, Margaret T ^a   Block, Annemarie W ^a   Lee, Kelvin ^a   Chanan Khan, Asher Alban ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Myeloma and CLL Consortium of Western NY   (United States)

^c St Vincent Hospital   (United States)

Author keywords

Chronic lymphocytic leukemia; Fludarabine refractory; High risk cytogenetics; Lenalidomide

Indexed keywords

LENALIDOMIDE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GENETIC RISK; HIGH RISK PATIENT; HUMAN; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR FLARE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; CYTOGENETICS; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PROGNOSIS; RECURRENCE; RISK; THALIDOMIDE; TREATMENT OUTCOME;

EID: 74949083498     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903406806     Document Type: Article

References (18)

1. Krober A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-1416.
2. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
3. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92:1242-1245.
4. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24:437-443.
5. Catovsky D. The changing face of chronic lymphocytic leukemia. Leuk Lymphoma 2007;48:2283-2284.
6. Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-2522.
7. Zenz T, Dohner H, Stilgenbauer S. Genetics and riskstratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007;20:439-453.
8. Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969-975.
9. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799-804.
10. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24:4634-4641.
11. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85: 1580-1589.
12. Byrd JC, Smith L, Hackbarth ML, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003;63: 36-38.
13. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-3281.
14. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab (Campath) in fludarabine-refractory CLL: final results of the CLL2H trial of the GCLLSG and comprehensive analysis of prognostic markers. Blood 2008;112(Supp. 11): Abstract 329.
15. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36-45.
16. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-5349.
17. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
18. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111: 5291-5297.